The global glycomic therapeutics market is expected to expand at a CAGR of 16.1% during the period 2022-2032. The market is expected to hold a valuation of US$ 551,756 million by 2032, and as of 2022, the market is valued at US$ 124,439 million.
The global glycomic therapeutics market is driven by the increasing understanding of the role of glycans in disease and the growing interest in developing drugs that target these molecules. The market is also driven by the availability of advanced technologies, such as mass spectrometry and glycan microarrays, that enable the analysis and manipulation of glycans.
The glycomic therapeutics market is segmented based on product type, application, end-user, and geography. The product type segment includes drugs and biologics. The application segment includes cancer, inflammation, infectious diseases, and others. The end-user segment includes hospitals, clinics, and research institutes. The cancer segment dominates the market due to the high prevalence of the disease and the growing interest in developing glycan-targeted therapies for cancer.
- Intellihep Ltd
- Protalix Biotherapeutics
- BioMarin Pharmaceutical Inc.
- Halozyme Therapeutics Inc
- Bayer AG
- Alzheon Inc.
- GlaxoSmithKline Plc
- Hoffmann-La Roche Ltd
Buy the Full Report Now @ https://www.persistencemarketresearch.com/checkout/33227
North America is the largest market for glycomic therapeutics, primarily due to the presence of a large number of pharmaceutical and biotechnology companies, the availability of advanced technologies, and the favorable regulatory environment. Europe is the second-largest market for glycomic therapeutics, followed by the Asia Pacific region. The Asia Pacific region is expected to experience significant growth in the coming years due to the increasing focus on drug discovery and development, the growing prevalence of chronic diseases, and the rising healthcare expenditure.
In conclusion, the glycomic therapeutics market is driven by the increasing understanding of the role of glycans in disease and the growing interest in developing drugs that target these molecules. The market is segmented based on product type, application, end-user, and geography, and is dominated by North America. The major players in the market are focused on developing new therapies and expanding their market presence through collaborations and partnerships.
Glycomic Therapeutics Market Segmentation
- Targeting Sialic Acid
- Targeting Glycosaminoglycans
- Targeting Glycosylphosphatidylinositol (GPI) – Anchored Proteins and Heparin Based Glycans
- Targeting Glycosphingolipids
- Thrombosis and Chemoprophylaxis
- Anti-adhesive and Anti-inflammatory
- Gaucher’s disease
- MPS-1 and IV
- Alzheimer’s disease
- Influenza type A and B
By Mode of Action:
- Inhibits Neuraminidase
- Inhibits Heparanase and Selectins and Blocks Interactions between Growth Factors and Heparan Sulfate
- Erythropoietin and Enzyme Replacement Therapy
- Tissue Plasminogen Activator
- Inhibits Glucosylceramide Synthase
- Interleukin 1, 2 & 3
- Beta and Gamma Interferons
- North America
- Latin America
- Asia Pacific
For More Premium Insights, Check out the Link:
Rheumatoid Arthritis Treatment Market
Persistence Market Research is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. Persistence Market Research boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, semiconductors and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – [email protected]